Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP0777
- Development stage
- Phase 1
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASP0777 is a synthetic small molecule drug developed by Astellas Pharma as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. It was investigated for the treatment of Alzheimer's disease, with the aim to improve symptoms by modulating glutamatergic neurotransmission in the brain. The drug acts as an NMDA receptor antagonist and was administered orally in clinical trials. Preclinical studies demonstrated good brain penetration and dose-dependent distribution in primate models[4]. Clinical development reached Phase 1, where safety and tolerability were evaluated in patients with Alzheimer's disease already receiving donepezil[5][2][3].
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ASP0777.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP0777.